Alligator Bioscience and PolyTherics announce strategic collaboration for optimisation of next generation biopharmaceuticals
Alligator Bioscience AB and PolyTherics Ltd announced the establishment of a new alliance. Under the terms of the collaboration agreement, PolyTherics and Alligator will explore the biological effects of the polymer-based technologies developed by PolyTherics on proteins optimized and provided by Alligator. The parties intend to use the intellectual property generated by their collaboration to explore the development and commercialization potential of next generation protein-based products. No further details were disclosed.
Dr Gun-Britt Fransson, Chief Executive Officer of Alligator, commented: "The collaboration with PolyTherics supports Alligator's strategy to further expand its pipeline with optimised drug candidates into new areas of indications. We are excited to see the outcome of combining the two companies' technologies."
Dr Keith Powell, Chief Executive Officer of PolyTherics, said: "A key element of PolyTherics' business strategy is to exploit our proprietary technologies in expanding the product potential of proteins. We have developed and continue to develop technologies to improve every type of protein therapeutic; from antibody fragments to enzymes, both natural and improved. We are excited by the prospects for this collaboration with Alligator and our shared vision of exploring next generation biopharmaceuticals."
Most read news
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents

OrganoTherapeutics SARL - Esch-sur-Alzette, Luxembourg
Study finds breast and ovarian cancer may have similar origins
Evonik ends cooperation with Chr. Hansen
Category:Female_sexual_dysfunction_drugs

Frederick W. Alt and David G. Schatz to be awarded the 2023 Paul Ehrlich and Ludwig Darmstaedter Prize - Laureates raised knowledge of the development of the immune system to a new level
Chemotherapy timing is key to success - Nanoparticles that stagger delivery of 2 drugs knock out aggressive tumors in mice

Call for Entries: Eppendorf & Science Prize for Neurobiology 2017
